137 related articles for article (PubMed ID: 36357737)
1. The pattern of failure after Stereotactic Radiation Therapy (SRT) for oligo-metastases: predictive factors for poly-progression.
Franceschini D; Cozzi L; Vernier V; Marzo AM; Marini B; Stefanini S; Navarria P; Scorsetti M
J Cancer Res Clin Oncol; 2023 Jul; 149(8):5173-5179. PubMed ID: 36357737
[TBL] [Abstract][Full Text] [Related]
2. Oligo-recurrence predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy: a multi-institutional study of 61 subjects.
Niibe Y; Nishimura T; Inoue T; Karasawa K; Shioyama Y; Jingu K; Shirato H
BMC Cancer; 2016 Aug; 16(1):659. PubMed ID: 27542716
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic radiotherapy combined with immunotherapy or targeted therapy for metastatic renal cell carcinoma.
Kroeze SGC; Fritz C; Schaule J; Siva S; Kahl KH; Sundahl N; Blanck O; Kaul D; Adebahr S; Verhoeff JJC; Skazikis G; Roeder F; Geier M; Eckert F; Guckenberger M
BJU Int; 2021 Jun; 127(6):703-711. PubMed ID: 33113260
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of salvage stereotactic radiotherapy (SRT) for locally recurrent brain metastases after initial SRT and characteristics of target population.
Holub K; Louvel G
Clin Transl Oncol; 2021 Jul; 23(7):1463-1473. PubMed ID: 33464481
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of MR Imaging Texture Analysis in Brain Non-Small Cell Lung Cancer Oligo-Metastases Undergoing Stereotactic Irradiation.
Nardone V; Tini P; Biondi M; Sebaste L; Vanzi E; De Otto G; Rubino G; Carfagno T; Battaglia G; Pastina P; Cerase A; Mazzoni LN; Banci Buonamici F; Pirtoli L
Cureus; 2016 Apr; 8(4):e584. PubMed ID: 27226944
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic Radiotherapy for the Treatment of Patients With Oligo-progressive Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor: Data From the Real World.
Gebbia V; Girlando A; DI Grazia A; Fazio I; Borsellino N; Piazza D; Serretta V; Pergolizzi S; Pontoriero A; Firenze A; Valerio MR
Anticancer Res; 2020 Dec; 40(12):7037-7043. PubMed ID: 33288600
[TBL] [Abstract][Full Text] [Related]
7. Additional chemotherapy improved local control and overall survival after stereotactic body radiation therapy for patients with oligo-recurrence.
Nakamura M; Hashimoto N; Mayahara H; Uezono H; Harada A; Nishikawa R; Matsuo Y; Kawaguchi H; Nishimura H
Radiat Oncol; 2018 Apr; 13(1):75. PubMed ID: 29688858
[TBL] [Abstract][Full Text] [Related]
8. A review of ongoing trials of stereotactic ablative radiotherapy for oligometastatic disease in the context of new consensus definitions.
Li GJ; Arifin AJ; Al-Shafa F; Cheung P; Rodrigues GB; Palma DA; Louie AV
Ann Palliat Med; 2021 May; 10(5):6045-6051. PubMed ID: 32787370
[TBL] [Abstract][Full Text] [Related]
9. Radionecrosis after repeated courses of radiotherapy under stereotactic conditions for brain metastases: Analysis of clinical and dosimetric data from a retrospective cohort of 184 patients.
Kuntz L; Le Fèvre C; Jarnet D; Keller A; Meyer P; Cox DG; Bund C; Antoni D; Cebula H; Noel G
Cancer Radiother; 2022 Sep; 26(5):692-702. PubMed ID: 35715354
[TBL] [Abstract][Full Text] [Related]
10. Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how?
Marvaso G; Corrao G; Oneta O; Pepa M; Zaffaroni M; Corso F; Gandini S; Cecconi A; Zerini D; Mazzola GC; Augugliaro M; Cossu Rocca M; Verri E; Cattani F; La Fauci F; Bergamaschi L; Luzzago S; Mistretta AF; Musi G; Nolè F; De Cobelli O; Orecchia R; Jereczek-Fossa BA
Clin Transl Oncol; 2021 Aug; 23(8):1717-1726. PubMed ID: 33687659
[TBL] [Abstract][Full Text] [Related]
11. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
[TBL] [Abstract][Full Text] [Related]
12. Impact of 2-staged stereotactic radiosurgery for treatment of brain metastases ≥ 2 cm.
Angelov L; Mohammadi AM; Bennett EE; Abbassy M; Elson P; Chao ST; Montgomery JS; Habboub G; Vogelbaum MA; Suh JH; Murphy ES; Ahluwalia MS; Nagel SJ; Barnett GH
J Neurosurg; 2018 Aug; 129(2):366-382. PubMed ID: 28937324
[TBL] [Abstract][Full Text] [Related]
13. Acute toxicities and cumulative dose to the brain of repeated sessions of stereotactic radiotherapy (SRT) for brain metastases: a retrospective study of 184 patients.
Kuntz L; Le Fèvre C; Jarnet D; Keller A; Meyer P; Thiery A; Cebula H; Noel G; Antoni D
Radiat Oncol; 2023 Jan; 18(1):7. PubMed ID: 36627646
[TBL] [Abstract][Full Text] [Related]
14. Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with "curative" intent.
Buglione M; Jereczek-Fossa BA; Bonù ML; Franceschini D; Fodor A; Zanetti IB; Gerardi MA; Borghetti P; Tomasini D; Di Muzio NG; Oneta O; Scorsetti M; Franzese C; Romanelli P; Catalano G; Dell'Oca I; Beltramo G; Ivaldi GB; Laudati A; Magrini SM; Antognoni P;
Lung Cancer; 2020 Mar; 141():1-8. PubMed ID: 31926440
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic radiosurgery versus stereotactic radiotherapy in the management of intracranial meningiomas: a systematic review and meta-analysis.
Fatima N; Meola A; Pollom EL; Soltys SG; Chang SD
Neurosurg Focus; 2019 Jun; 46(6):E2. PubMed ID: 31153149
[TBL] [Abstract][Full Text] [Related]
16. Distance to isocenter is not associated with an increased risk for local failure in LINAC-based single-isocenter SRS or SRT for multiple brain metastases.
Kraft J; van Timmeren JE; Mayinger M; Frei S; Borsky K; Stark LS; Krayenbuehl J; Zamburlini M; Guckenberger M; Tanadini-Lang S; Andratschke N
Radiother Oncol; 2021 Jun; 159():168-175. PubMed ID: 33798610
[TBL] [Abstract][Full Text] [Related]
17. Additional bevacizumab in EGFR-mutant lung adenocarcinoma patients who had oligo-progression after the failure of EGFR-TKI: A single-institute retrospective study.
Kashiwabara K; Fujii S; Tsumura S; Sakamoto K; Semba H
Cancer Treat Res Commun; 2020; 22():100163. PubMed ID: 31675534
[TBL] [Abstract][Full Text] [Related]
18. Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases.
Frakes JM; Figura NB; Ahmed KA; Juan TH; Patel N; Latifi K; Sarangkasiri S; Strom TJ; Chinnaiyan P; Rao NG; Etame AB
J Neurosurg; 2015 Nov; 123(5):1261-7. PubMed ID: 26140482
[TBL] [Abstract][Full Text] [Related]
19. Single fraction stereotactic radiosurgery and fractionated stereotactic radiotherapy provide equal prognosis with overall survival in patients with brain metastases at diagnosis without surgery at primary site.
Ostdiek-Wille GP; Amin S; Wang S; Zhang C; Lin C
PeerJ; 2023; 11():e15357. PubMed ID: 37223122
[TBL] [Abstract][Full Text] [Related]
20. Prescription dose and fractionation predict improved survival after stereotactic radiotherapy for brainstem metastases.
Leeman JE; Clump DA; Wegner RE; Heron DE; Burton SA; Mintz AH
Radiat Oncol; 2012 Jul; 7():107. PubMed ID: 22784482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
